Acceleron Pharma (XLRN) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results
November 4, 2015 7:01 AM ESTACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year
ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year
FDA granted Fast Track Designation for dalantercept in combination with axitinib for the treatment of patients with advanced renal cell carcinoma
Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and beta-thalassemia expected to begin by year-end 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:... More
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
November 4, 2015 6:58 AM ESTCAMBRIDGE, Mass., Nov. 4, 2015 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million.
Evelo is pioneering Oncobiotic therapeutics, a new modality in cancer therapy based on the cancer microbiome. Evelo is the first company to systematically... More
